Serum Institute of India (SII) CEO Adar Poonawala on Thursday announced the decision to bid for the defending Champions of the Indian Premier League (IPL) Royal Challengers Bengaluru (RCB).
Adar Poonawalla, CEO of Serum Institute of India, has hinted at the prospect of purchasing a stake in the Indian Premier League franchise Royal Challengers Bengaluru (RCB).
Serum Institute of India (SII) held the 'Conquer HPV and Cancer Conclave' in Visakhapatnam, Andhra Pradesh, to spread awareness regarding the sexually transmitted infection Human Papillomavirus (HPV).
In a major feat, the Serum Institute of India (SII) has shipped its first set of R21/Matrix-M Malaria vaccine doses to the Africa region, which has a sizable disease burden.
"With India achieving high vaccination rates in 2021 and 2022, coupled with the emergence of new mutant variant strains, the demand for previous vaccines diminished significantly. Consequently, since December 2021, we have stopped the manufacturing and supply of additional doses of Covishiel
Medical expert Dr MV Padma Srivastava said that there are rare cases of side effects from vaccines adding that the occurring percentage of the side effects is "very low."
This collaboration, announced today, aims to bolster the production and supply security of Oral Polio Vaccines (OPV), a crucial step towards achieving a polio-free world.
While addressing people at an award programme in Pune, Maharashtra, on Wednesday, where Cyrus Poonawala was also present, Sharad Pawar pointed out how the Serum Institute's vaccine has proved effective for many diseases, including COVID, and how big their contribution is.
The National Technical Advisory Group for Immunisation (NTAGI) has recommended introduction of The quadrivalent Human Papilloma Virus (qHPV) vaccine in the Universal Immunization Programme (UIP) with a one-time catch-up for 9-14 year-old adolescent girls followed with routine introduction
The world's largest vaccine manufacturer, the Serum Institute of India Private Ltd (SII), is joining a growing Coalition for Epidemic Preparedness Innovations (CEPI) network of vaccine producers in the Global South to support more rapid, agile, and equitable responses to future public health
As malaria vaccine developed by the University of Oxford and the Serum Institute of India (SII) has been recommended for use by the World Health Organisation (WHO), SII chief Adar Poonawalla said that the combined efforts of both of them have come to fruition.